ImmuPharma (LSE:IMM) is a pharmaceutical company focusing on developing novel medicines in specialist markets with serious unmet need.
ImmuPharma has a number of drugs in development, each
representing a significant breakthrough in its
field. The company’s most advanced drug
candidate, Lupuzor™, has started phase III after receiving the
approval from the US FDA to enter phase III with
a Special Protocol Assessment and “Fast Track”
ImmuPharma plc is led by a
commercially focused Board and management team with
extensive experience and is headquartered in London and
has its research operations in France (ImmuPharma
(France) SA) and Switzerland (ImmuPharma AG).
ImmuPharma has an important collaboration arrangement with the Centre National de la Recherche Scientifique (CNRS), the French National Council for Scientific Research. Lupuzor™ was successfully licensed to the large US specialist pharmaceutical company Cephalon Inc. in 2009. Due to the takeover of Cephalon by Teva Pharmaceuticals Inc in 2011, ImmuPharma regained all rights to Lupuzor™.
IPP-204106 for the treatment of multiple cancers plus molecules of the same chemical family for other indications
IPP-102199 for the treatment of moderate to severe pain
IPP-203101 for the treatment of MRSA and other severe infections
IPP-201007 for the treatment of inflammatory diseases
Library of over 300,000 small molecules and peptides (foldamers)
Peptide Delivery Technology
Novel projects in collaboration with the CNRS
our scientific leadership team
Dr Robert Zimmer, MD, PhD
President and Chief Science Officer, ImmuPharma plc
Dr. Robert Zimmer was the founder of both ImmuPharma Switzerland and ImmuPharma France.
He began his career in Roche’s headquarters in
Basle as coordinator of clinical pharmacology
and international clinical leader. He
subsequently joined Jago Pharma, the drug
delivery company, and became a director and head
of research and development at SkyePharma plc
after it acquired Jago. He was instrumental in developing a number of products for Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.
Prof Sylviane Muller, PhD
Research Director at CNRS and Co-founder of ImmuPharma France
Dr Muller, the key inventor of Lupuzor, is a
Distinguished class Research Director at the
CNRS (Centre National de la Recherche
Scientifique) and head of the
“Immunologie et chimie thérapeutiques” unit,
Her field of expertise covers autoimmunity,
immuno-peptides and synthetic vaccines. She has
made 23 patented discoveries and was also a founder of Neosystem,
now Polypeptide, a leading peptide
development and manufacturing company. She obtained her PhD at the
University of Strasbourg and spent two years in Max-Planck Institute
for Immunobiology in Freiburg, Germany. Sylviane Muller received
the CNRS Innovation Medal 2015, a prestigious award recognizing
individuals whose outstanding research leads to breakthrough
innovations in terms of technological, medical and commercial applications.
Dr Jean-Paul Briand, PhD
Research Director at CNRS and Co-founder of ImmuPharma France
Dr Briand is CNRS Research Director at the “Immunologie et chimie thérapeutiques” unit of the Centre National de la Recherche Scientifique, the largest scientific research institution in France. He is co-inventor of Lupuzor and Nucant molecules (ImmuPharma’s anticancer programme). He has extensive industry experience in peptide chemistry and synthesis in Peninsula, USA and was also a founder of Neosystem, now Polypeptide, a leading peptide development and manufacturing company.
Dr Gilles Guichard, PhD
Research Director, CNRS
and Co-founder of ImmuPharma France
Gilles Guichard is a CNRS Research Director. His current research focuses on
peptidomimetic and foldamer chemistry. He studied chemistry at
the École Nationale Supérieure de Chimie in
Toulouse and at the University of Montpellier in
France. He received his PhD from the University
of Strasbourg. After
post-doctoral research with Prof. Dieter Seebach
at the ETH Zürich (Switzerland) working in the
field of β-peptide foldamers, he joined the
Institut de Biologie Moléculaire et Cellulaire
in Strasbourg, He moved to the Institut Européen
de Chimie et Biologie (IECB) in Bordeaux, France
as a new group leader.
The aim of the Strasbourg CNRS team headed by Prof. Sylviane Muller is to understand the molecular and cellular bases of autoimmune response and starting for information obtained from these studies, to identify novel therapeutic approaches to specifically treat systemic autoimmune diseases. The key theme of the research Unit is Lupus. The laboratory comprises 60 researchers, engineers, technicians, postdoctoral fellows, PhD and Master students, almost all involved in investigation centered to Lupus. Over years researchers and staff have gained a long-lasting and strong experience and know-how in this area. They have access to a number of advanced technologies and also to spontaneous or induced mouse models on which it is possible to investigate genetic, cellular and molecular processes involved in the disease as well as therapeutic approaches without interference with concomitant medication. Besides the development of new drugs designed for treating patients with Lupus, the centres of interest of team leaders of the Unit are to better understand the influence of genetic and environmental factors in the etiology of Lupus, the reasons for the immune breakdown of tolerance that leads to the disease, the possible link between cutaneous tissues and the immune system and how they may interact to regulate the balance between immunity and tolerance, and many other aspects of the cellular and molecular dysfunction of the immune system in animal and patients affected by Lupus. The laboratory is an active partner of several European and French Lupus networks, and several of its members are regularly invited to present their latest data in international workshops and congresses. The force of the Laboratory is to associate fundamental scientists and active clinicians as well as experts in different technological areas (biologists, chemists, pharmacologists, physicians) who all focus their efforts on Lupus condition. The laboratory coordinates several major programs on Lupus, and is heading the European Lupus cohort project associating several German and French Centres, the Laboratory of Excellence Medalis (centre of drug discovery focused on inflammatory diseases and cancer) and the reference center for rare autoimmune diseases.
Prof Muller's academic pageProf Muller's Innovation MedalIBMC Strasbourg TeamCNRS Immunology Department